[Asia Economy Reporter Hyunseok Yoo] GobioLab, a company specializing in microbiome new drug development, is showing strong performance. This is interpreted as a stock price surge following expectations of technology transfer and the government's announcement of support measures.
As of 1:41 PM on the 22nd, GobioLab was trading at 44,850 KRW, up 18.03% (6,050 KRW) compared to the previous trading day.
The Ministry of Food and Drug Safety announced on the same day that it will operate the 'Microbiome Therapeutics Product Support Team,' which focuses on new drug development using microorganisms and genetic information within the market.
Microbiome refers to the entire genetic information of microorganisms or the microorganisms themselves existing in a specific environment. Currently, there are 204 microbiome therapeutics under development worldwide. The market size is expected to increase 167-fold from $56.3 million (approximately 62.3 billion KRW) in 2018 to $9.3875 billion (10.392 trillion KRW) in 2024.
The Ministry of Food and Drug Safety formed the support team with three divisions: the Pre-consultation Department of the National Institute of Food and Drug Safety Evaluation, the related review department, and the research department. They plan to establish guidelines and approval review standards considering the characteristics of microbiomes, including quality, non-clinical, and clinical data requirements.
On the same day, GobioLab announced its intention to pursue technology transfer by participating in the JPM Healthcare Conference. During the conference, they plan to actively engage in partnering discussions, focusing on global pharmaceutical companies with whom they have been discussing existing technology alliances. They will share the clinical progress of key microbiome new drug pipelines such as KBLP-001 and KBLP-002, which are immune disease projects currently undergoing global clinical trials, and deepen technology transfer discussions based on the results of mechanism of action research.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
